Group 1 - The company Gu Han Medicine has released an annual performance forecast, expecting a net profit attributable to shareholders of the listed company to be between -55 million and -45 million yuan for the year 2025 [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between -65 million and -55 million yuan for the same period [1] - The main reasons for the expected loss include: (1) Impact from industry policies and rising procurement costs of raw materials leading to a slight decline in overall gross profit [1] (2) Impairment testing and provision for goodwill related to the acquisition of Guangdong Xiantong's equity due to changes in industry trends and market conditions [1] (3) Provision for credit impairment of receivables based on accounting standards and the company's actual operating conditions [1]

古汉医药公告，预计2025年度净利润亏损4500万元至5500万元。受行业政策等因素影响，加之上游部分 原材料采购成本上涨，致使整体毛利略有下降。 ...

证券代码：000590 证券简称：古汉医药 公告编号：2026-003 古汉医药集团股份公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值 一、本期业绩预计情况 （1）以区间数进行业绩预告的 单位：万元 | 项 目 | | 本报告期 | | 上年同期 | | --- | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | -5,500 | ～ | -4,500 | -12,547.15 | | 扣除非经常性损益后的净利润 | -6,500 | ～ | -5,500 | -16,981.70 | | 基本每股收益（元/股） | -0.2297 | ～ | -0.1879 | -0.5240 | | 营业收入（如适用） | 32,000 | ～ | 34,500 | 34,320.81 | | 扣除后营业收入（如适用） | 30,500 | ～ | 32,000 | 33,767.68 | ...

证券日报网讯1月27日，古汉医药（000590）在互动平台回答投资者提问时表示，根据《深圳证券交易 所股票上市规则》的相关规定，若公司满足业绩预告相应条件，公司将在会计年度结束后的一个月内对 年度经营情况进行业绩预告，并确定披露相关事宜。 ...

Regulatory Actions - The China Securities Regulatory Commission (CSRC) has issued its first administrative penalty of the year, targeting market manipulation by individual Yu Han, who was fined over 1 billion yuan for manipulating the stock price of "Doctor Glasses" [1] - The Zhejiang Securities Regulatory Bureau has initiated an investigation into misleading statements related to the restructuring plan of "Sunflower" [1] - The Shenzhen Stock Exchange is closely monitoring *ST Cube and *ST Changyao due to allegations of false financial reporting, as indicated by the CSRC [1] Market Stability - Recent abnormal fluctuations in stocks facing delisting risks have drawn regulatory attention, highlighting a speculative mindset among market participants [2] - The CSRC has warned investors about the significant risks associated with *ST Cube and *ST Changyao, urging them to rely on official announcements and avoid being misled by false information [2] - The rapid response from regulatory bodies aims to curb irrational market speculation and maintain stable market operations [2] Legal Framework - Article 55 of the Securities Law prohibits individuals from manipulating the securities market using false or uncertain significant information to influence trading prices or volumes [3] - The regulatory framework is evolving to include collaborative governance with platforms, as seen with the recent permanent bans on 22 accounts on the Xueqiu platform for violations [3] Enforcement and Penalties - The CSRC has demonstrated a strong stance against market manipulation, with multiple cases being prosecuted this year, reflecting a zero-tolerance policy [4] - Yu Han's manipulation tactics included trading between accounts he controlled, resulting in a penalty exceeding 1 billion yuan [4] - The case of Jin Yongrong, who faced penalties exceeding 83 million yuan for misleading investors through social media, underscores the serious consequences of such actions [4] Long-term Regulatory Strategy - A multi-dimensional regulatory network is being established to create a long-term governance framework that discourages violations [5] - The judicial system is being refined to enhance legal protections for investors, making it easier for them to seek compensation for damages caused by market manipulation [5] - The integration of administrative and criminal enforcement is crucial for improving regulatory effectiveness and deterring illegal activities in the financial market [6] Technological Integration - The use of technology in regulation is becoming a trend, with recommendations for the application of big data and artificial intelligence to monitor and analyze suspicious trading activities [6] - Enhanced technological capabilities aim to shift regulatory focus from post-event investigations to proactive prevention and intervention [6]

Core Viewpoint - A significant number of companies in the A-share market have reported substantial losses, leading to a collective loss of 500 billion yuan, indicating a severe financial crisis within the industry [1][20]. Group 1: Company Losses - 65 companies disclosed their financial troubles, with major players like Red Star Macalline, Jindi Group, and Jianfa Holdings reporting massive losses of 225 billion, 135 billion, and 100 billion yuan respectively [4][10]. - The losses from these three companies alone could have been sufficient to acquire an entire medium-sized sector, highlighting the scale of the financial damage [5]. - The losses are attributed to asset impairment and the devaluation of previously overvalued properties, leading to a collapse in investor confidence [8][20]. Group 2: Market Reactions - The market appears to be in a state of denial, with indices showing resilience while individual stocks suffer severe declines, indicating a disconnect between market perception and reality [3][10]. - The financial reports have led to a significant drop in stock prices, undermining the belief in "core assets" and revealing the fragility of the market [10][20]. Group 3: Financial Strategies - The phenomenon of "financial big washing" is observed, where companies are using accounting flexibility to report massive losses in one go, potentially to reset their financial baselines for future reporting [17][20]. - This strategy allows companies to clear hidden liabilities and prepare for a potential recovery, but it also risks eroding investor trust [20][21]. Group 4: Regulatory Environment - The current regulatory environment, including the new registration system, has increased the pressure on companies to maintain transparency and avoid continuous losses, which could lead to delisting [21][22]. - Companies are advised to focus on fundamental performance rather than speculative trading, as the market is becoming increasingly unforgiving towards those with deteriorating fundamentals [21].

Core Viewpoint - The announcement from Anhui Securities Regulatory Commission highlights the significant risk of forced delisting for *ST Lifan due to major violations, urging investors to rely on official announcements and avoid being misled by false information [1][2] Group 1: Company Situation - *ST Lifan has been flagged for potential forced delisting due to suspected false financial reporting over three consecutive years (2021-2023), with inflated revenues of 280 million and 312 million yuan for 2021 and 2022, respectively, accounting for over 50% of annual revenues [2] - The company has received a notice of administrative penalty and market entry ban, with a proposed fine of 40 million yuan against *ST Lifan and ten responsible individuals [2] - Following a period of stock price decline, *ST Lifan's stock surged after the actual controller released optimistic statements about the company's situation, despite the company later clarifying it did not authorize such communications [3][4] Group 2: Market Reactions - Both *ST Lifan and *ST Changyao experienced significant stock price increases despite facing forced delisting risks, raising concerns about potential market manipulation [5][6] - The abnormal price movements of these stocks, which do not align with their fundamental risks, suggest possible speculative trading behavior that could mislead investors [7][8] Group 3: Regulatory Response - Regulatory authorities are urged to enhance monitoring of abnormal trading activities related to delisting risk stocks and to take timely actions such as inquiries and suspensions [8] - Experts emphasize the need for strict enforcement against any illegal activities during the delisting process, including false statements and market manipulation, to maintain the integrity of the capital market [8]

Group 1 - The Shanghai Stock Exchange (SSE) reported that from January 19 to 23, it took self-regulatory measures against 152 cases of abnormal trading behaviors, including price manipulation and false declarations [1] - The SSE focused on monitoring stocks with significant volatility, such as *ST Zhengping, *ST Yazhen, Guosheng Technology, Tiangpu Co., and Shangwei New Materials, and conducted special investigations on 20 major corporate events, reporting 3 suspected illegal cases to the China Securities Regulatory Commission (CSRC) [1] - The Shenzhen Stock Exchange (SZSE) took self-regulatory measures against 326 cases of abnormal trading behaviors during the same period, involving price manipulation and false declarations [1] Group 2 - The SZSE specifically monitored *ST Lifang and *ST Changyao, which are under investigation by the CSRC for suspected false financial reporting, and conducted investigations on 6 major corporate events, reporting 1 suspected illegal case to the CSRC [1] - The Beijing Stock Exchange (BSE) continued to monitor the delisting risk warning stock "*ST Yunchuang" and took self-regulatory measures against 17 cases of abnormal trading behaviors, including price manipulation and false declarations [1] - The BSE also conducted a special investigation on 1 major corporate event during this period [1]

Group 1 - The international standard "Cili Juice—Specification and test methods" (ISO/WD26093) has been successfully established, led by China National Pharmaceutical Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd. and Guizhou Natural Products Research Center in collaboration with the China Food Fermentation Industry Research Institute [1] - The project planning began in September 2024, with the formal proposal submitted to the International Organization for Standardization (ISO) in July 2025, and the proposal was approved after a three-month voting period [1] - The project involves experts from five countries, including Russia, Serbia, Sri Lanka, and Turkey, working together with the Chinese team to draft the standard, which is expected to be published in 2028 after a 36-month development period [1] Group 2 - Guizhou is the origin and leader of the Cili industry in China, with 1.52 million acres of planting area and a comprehensive output value of approximately 10 billion yuan, accounting for over 90% of the national share in planting area, processing capacity, and product variety [2] - The certification of the Cili juice under international standards is seen as a "green pass" for entering international markets, allowing products that meet these standards to achieve higher price premiums in the global market [2] - The establishment of international standards is expected to convert China's resource advantages into economic value, enhancing product quality and safety, promoting technological innovation, and facilitating international trade [2]

Core Viewpoint - Guhanshan Pharmaceutical is leveraging its partnership with Hengchang Pharmaceutical Group to expand its market reach and enhance product competitiveness, particularly focusing on its flagship product, Guhanshan Health Essence [1][2]. Group 1: Company Overview - Guhanshan Pharmaceutical, established in 1996, is the first pharmaceutical company listed in Hunan Province, with its core product, Guhanshan Health Essence, based on a 2200-year-old ancient health formula [1]. - The company has achieved remarkable sales performance, with Guhanshan Health Essence reportedly selling approximately 4 units per second in the Hunan OTC retail market [1]. Group 2: Strategic Developments - The company has undergone a control change in 2025, with Jiang Jin becoming the new actual controller, and has formed a strategic partnership with Hengchang Pharmaceutical Group, leading to a rebranding from "Qidi Pharmaceutical" to "Guhanshan Pharmaceutical" [1]. - Guhanshan Pharmaceutical aims to optimize its existing product lines and production capacity, with plans to restore production for over 30 varieties this year, focusing on achieving positive cash flow [2]. Group 3: Market Expansion and Collaboration - Hengchang Pharmaceutical Group currently serves over 200,000 member pharmacies and clinics, generating nearly 4 billion yuan in annual sales, which positions it as a significant partner for Guhanshan Pharmaceutical [2]. - The collaboration is expected to enhance the operational capabilities of both companies, creating a "front store and back factory" ecosystem that supports the growth of small and medium-sized pharmacies [2]. Group 4: Future Growth Strategies - Guhanshan Pharmaceutical plans to build a product matrix centered around Guhanshan Health Essence, while also expanding into chemical drugs and health food sectors [3]. - The company is focusing on integrating cultural tourism with traditional Chinese medicine and promoting intelligent, flexible production methods [3].